Inactive Instrument

Santhera Pharmaceuticals Holding AG Share Price Xetra

Equities

S3F

CH0027148649

Pharmaceuticals

Financials

Sales 2024 * 51.09M 56.96M 52.75M 4.76B Sales 2025 * 60M 66.89M 61.94M 5.59B Capitalization 88.46M 98.63M 91.33M 8.25B
Net income 2024 * -35M -39.02M -36.13M -3.26B Net income 2025 * -10M -11.15M -10.32M -932M EV / Sales 2024 * 1.73 x
Net cash position 2024 * - 0 0 0 Net cash position 2025 * - 0 0 0 EV / Sales 2025 * 1.47 x
P/E ratio 2024 *
-3.42 x
P/E ratio 2025 *
-12.8 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 65.98%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Santhera Pharmaceuticals Holding AG, 2023 Earnings Call, Apr 25, 2024
Santhera Pharmaceuticals Swings to Profit in FY23; Revenue Grows MT
Santhera Pharmaceuticals Holding AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Santhera Pharmaceuticals Holding AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis MT
Santhera Pharmaceuticals Wins Priority Review for Duchenne Muscular Dystrophy Drug in China MT
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Grants Priority Review by China's NMPA CI
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical?s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology CI
Santhera's New Study Shows Efficacy, Safety Data for Duchenne Muscular Dystrophy Treatment MT
Santhera Pharmaceuticals Holding AG Launches AGAMREE in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy CI
Swiss Equities Get a Boost from UK’s Upside GDP Surprise MT
Santhera Pharmaceuticals Obtains UK Approval for Duchenne Muscular Dystrophy Treatment MT
Swiss Equities Edge Down After Central Banks Buzz MT
Santhera Pharmaceuticals Wins EU Nod for Duchenne Muscular Dystrophy Drug MT
Santhera Pharmaceuticals Names Chief Commercial, Technology Officers MT
More news

Latest transcript on Santhera Pharmaceuticals Holding AG

Managers TitleAgeSince
Chief Executive Officer 56 01/19/01
Founder 62 07/04/07
Director of Finance/CFO 61 01/20/01
Members of the board TitleAgeSince
Founder 62 07/04/07
Director/Board Member 56 04/17/04
Director/Board Member 68 27/23/27
More insiders
Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
Calendar
More about the company